<p>瑞穗證券分析師 Graig Suvannavejh 今天對 Axsome Therapeutics 維持了買入評級，並設定了 310.00 美元的目標價。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Suvannavejh 覆蓋醫療保健行業，關注 Insmed、Verastem 和 Immuneering 等股票。根據 TipRanks 的數據，Suvannavejh 的平均回報率為 19.9%，推薦股票的成功率為 48.98%。</p>
<p>除了瑞穗證券，Axsome Therapeutics 還在今天的報告中獲得了 H.C. Wainwright 的 Ram Selvaraju 的買入評級。然而，在同一天，摩根士丹利對 Axsome Therapeutics（NASDAQ: AXSM）維持了持有評級。</p>

AXSM

<p>瑞穗證券分析師 Graig Suvannavejh 對 Axsome Therapeutics (AXSM) 維持買入評級，目標價為 310.00 美元。Suvannavejh 專注於醫療保健行業，其股票推薦的平均回報率為 19.9%，成功率為 48.98%。此外，H.C. Wainwright 的 Ram Selvaraju 也對 Axsome Therapeutics 發佈了買入評級，而摩根士丹利則對該股票維持持有評級</p>

<p>Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics today and set a price target of $310.00.</p>
<div class="lb-trans"><p>瑞穗證券分析師 Graig Suvannavejh 今天對 Axsome Therapeutics 維持了買入評級，並設定了 310.00 美元的目標價。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Suvannavejh covers the Healthcare sector, focusing on stocks such as Insmed, Verastem, and Immuneering. According to TipRanks, Suvannavejh has an average return of 19.9% and a 48.98% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Suvannavejh 覆蓋醫療保健行業，關注 Insmed、Verastem 和 Immuneering 等股票。根據 TipRanks 的數據，Suvannavejh 的平均回報率為 19.9%，推薦股票的成功率為 48.98%。</p>
</div><p>In addition to Mizuho Securities, Axsome Therapeutics also received a Buy from H.C. Wainwright’s Ram Selvaraju in a report issued today. However, on the same day, Morgan Stanley maintained a Hold rating on Axsome Therapeutics (NASDAQ: AXSM).</p>
<div class="lb-trans"><p>除了瑞穗證券，Axsome Therapeutics 還在今天的報告中獲得了 H.C. Wainwright 的 Ram Selvaraju 的買入評級。然而，在同一天，摩根士丹利對 Axsome Therapeutics（NASDAQ: AXSM）維持了持有評級。</p>
</div>

Mizuho Securities Keeps Their Buy Rating on Axsome Therapeutics (AXSM)

Tip Ranks

Axsome Therap

Mizuho Financial Group, Inc.

瑞穗金融集團

Insmed

Verastem

Immuneering

摩根士丹利

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

瑞穗證券維持對 Axsome Therapeutics（AXSM）的買入評級